Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma
Katelyn T. Byrne, … , Edward J. Usherwood, Mary Jo Turk
Katelyn T. Byrne, … , Edward J. Usherwood, Mary Jo Turk
Published April 11, 2011
Citation Information: J Clin Invest. 2011;121(5):1797-1809. https://doi.org/10.1172/JCI44849.
View: Text | PDF
Research Article Oncology

Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma

  • Text
  • PDF
Abstract

A link between autoimmunity and improved antitumor immunity has long been recognized, although the exact mechanistic relationship between these two phenomena remains unclear. In the present study we have found that vitiligo, the autoimmune destruction of melanocytes, generates self antigen required for mounting persistent and protective memory CD8+ T cell responses to melanoma. Vitiligo developed in approximately 60% of mice that were depleted of regulatory CD4+ T cells and then subjected to surgical excision of large established B16 melanomas. Mice with vitiligo generated 10-fold larger populations of CD8+ memory T cells specific for shared melanoma/melanocyte antigens. CD8+ T cells in mice with vitiligo acquired phenotypic and functional characteristics of effector memory, suggesting that they were supported by ongoing antigen stimulation. Such responses were not generated in melanocyte-deficient mice, indicating a requirement for melanocyte destruction in maintaining CD8+ T cell immunity to melanoma. Vitiligo-associated memory CD8+ T cells provided durable tumor protection, were capable of mounting a rapid recall response to melanoma, and did not demonstrate phenotypic or functional signs of exhaustion even after many months of exposure to antigen. This work establishes melanocyte destruction as a key determinant of lasting melanoma-reactive immune responses, thus illustrating that immune-mediated destruction of normal tissues can perpetuate adaptive immune responses to cancer.

Authors

Katelyn T. Byrne, Anik L. Côté, Peisheng Zhang, Shannon M. Steinberg, Yanxia Guo, Rameeza Allie, Weijun Zhang, Marc S. Ernstoff, Edward J. Usherwood, Mary Jo Turk

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 Total
Citations: 1 4 2 5 6 3 2 1 1 2 2 3 5 2 2 1 42
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (42)

Title and authors Publication Year
Cancer therapy via neoepitope-specific monoclonal antibody cocktails
Hartman CJ, Mohamed AO, Shukla GS, Pero SC, Sun YJ, Rodríguez-Jimenez RS, Genovese NF, Kohler NM, Hemphill TR, Huang YH, Krag DN, Ackerman ME
Cancer Immunology, Immunotherapy : CII 2025
CD39 is expressed on functional effector and tissue resident memory CD8+ T cells
Isaacs JF, Degefu HN, Chen T, Kleist SA, Musial SC, Ford MA, Searles TG, Lin CC, Skorput AG, Shirai K, Turk MJ, Zanazzi GJ, Rosato PC
Journal of immunology (Baltimore, Md. : 1950) 2024
Cancer therapy-induced dermatotoxicity as a window to understanding skin immunity
Jiménez-Andrade Y, Flesher JL, Park JM
Hematology/oncology clinics of North America 2024
Depletion of conventional CD4(+) T cells is required for robust priming and dissemination of tumor antigen-specific CD8(+) T cells in the setting of anti-CD4 therapy.
Ramirez DE, Dragnev CPC, Searles TG, Spicer N, Chen T, Lines JL, Hawkes AR, Davis WL, Mohamed A, Shirai K, Phillips JD, Rosato PC, Huang YH, Turk MJ
Journal for immunotherapy of cancer 2024
Challenges faced when identifying patients for combination immunotherapy
Ernstoff MS, Gandhi S, Pandey M, Puzanov I, Grivas P, Montero A, Velcheti V, Turk MJ, Diaz-Montero CM, Lewis LD, Morrison C
Future Oncology 2024
Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma
Liu D, Yang F, Zhang T, Mao R
Journal of Translational Medicine 2023
Transient regulatory-T-cell interruption promotes skin-resident memory T cells mediated tumor protection.
Zhao S, Wu S, Jiang S, Zhou X, Zhao G, Wang B
Scientific Reports 2023
The evolving role of tissue-resident memory T cells in infections and cancer.
Yenyuwadee S, Sanchez-Trincado Lopez JL, Shah R, Rosato PC, Boussiotis VA
Science Advances 2022
A mouse model of vitiligo based on endogenous auto-reactive CD8 + T cell targeting skin melanocyte
Chen D, Xu Z, Cui J, Chen T
Cell Regeneration 2022
Clinical significance and immune landscape of KIR2DL4 and the senescence‐based signature in cutaneous melanoma
Mao R, Ren Z, Yang F, Yang P, Zhang T
Cancer Science 2022
Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis.
Zhao F, Zhu J, Yu R, Shao T, Chen S, Zhang G, Shu Q
Scientific Reports 2022
Pro- and Anti-Tumoral Factors Involved in Total Body Irradiation and Interleukin-2 Conditioning in Adoptive T Cell Therapy of Melanoma-Bearing Rag1 Knock-Out Mice
Kim SH, Go EM, Shin DH, Choi BK, Han C
Cells 2022
Autoimmunity affecting the biliary tract fuels the immunosurveillance of cholangiocarcinoma
J Paillet, C Plantureux, S Lévesque, JL Naour, G Stoll, A Sauvat, P Caudana, JT Boari, N Bloy, S Lachkar, I Martins, P Opolon, A Checcoli, A Delaune, N Robil, P de la Grange, J Hamroune, F Letourneur, G Autret, PS Leung, ME Gershwin, JS Zhu, MJ Kurth, B Lekbaby, J Augustin, Y Kim, S Gujar, C Coulouarn, L Fouassier, L Zitvogel, E Piaggio, C Housset, P Soussan, MC Maiuri, G Kroemer, JG Pol
Journal of Experimental Medicine 2021
Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18Rαhi CD8+ T cells
SH Kim, E Cho, YI Kim, C Han, BK Choi, BS Kwon
Nature Communications 2021
Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity
JL Collier, SA Weiss, KE Pauken, DR Sen, AH Sharpe
Nature Immunology 2021
Dendritic cells maintain anti-tumor immunity by positioning CD8 skin-resident memory T cells
JL Vella, A Molodtsov, CV Angeles, BR Branchini, MJ Turk, YH Huang
Life science alliance 2021
CD8+ T cell self-tolerance permits responsiveness but limits tissue damage
Truckenbrod EN, Burrack KS, Knutson TP, Borges da Silva H, Block KE, O'Flanagan SD, Stagliano KR, Hurwitz AA, Fulton RB, Renkema KR, Jameson SC
eLife 2021
Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma.
Molodtsov AK, Khatwani N, Vella JL, Lewis KA, Zhao Y, Han J, Sullivan DE, Searles TG, Preiss NK, Shabaneh TB, Zhang P, Hawkes AR, Malik BT, Kolling FW 4th, Usherwood EJ, Wong SL, Phillips JD, Shirai K, Angeles CV, Yan S, Curiel TJ, Huang YH, Cheng C, Turk MJ
Immunity 2021
Neuropilin-1 is a T cell memory checkpoint limiting long-term anti-tumor immunity
Liu C, Somasundaram A, Manne S, Gocher AM, Szymczak-Workman AL, Vignali KM, Scott EN, Normolle DP, Wherry EJ, Lipson EJ, Ferris RL, Bruno TC, Workman CJ, Vignali DA
Nature Immunology 2020
Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy
Yazdani M, Hatamipour M, Alani B, Nikzad H, Mohamadian Roshan N, Verdi J, Jaafari MR, Noureddini M, Badiee A
Iranian Journal of Basic Medical Sciences 2020
Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors
RAMONDETTA A, RIBERO S, CONTI L, FAVA P, MARRA E, BROGANELLI P, CALIENDO V, PICCIOTTO F, GUIDA M, FIERRO MT, QUAGLINO P
Acta Dermato Venereologica 2020
Skin‐resident memory T cells as a potential new therapeutic target in vitiligo and melanoma
M Willemsen, R Linkutė, RM Luiten, TR Matos
Pigment Cell & Melanoma Research 2019
Melanoma and Vitiligo: In Good Company
CM Failla, ML Carbone, C Fortes, G Pagnanelli, S DAtri
International journal of molecular sciences 2019
Tissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity
A Molodtsov, MJ Turk
Frontiers in immunology 2018
Resident memory T cells in the skin mediate durable immunity to melanoma
BT Malik, KT Byrne, JL Vella, P Zhang, TB Shabaneh, SM Steinberg, AK Molodtsov, JS Bowers, CV Angeles, CM Paulos, YH Huang, MJ Turk
Science Immunology 2017
Optimizing T-cell receptor gene therapy for hematologic malignancies
EC Morris, HJ Stauss
Blood 2016
Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin
J Klarquist, JM Eby, SW Henning, M Li, DA Wainwright, W Westerhof, RM Luiten, MI Nishimura, IC le Poole
Pigment Cell & Melanoma Research 2016
Human T Cell Crosstalk Is Induced by Tumor Membrane Transfer
R Uzana, G Eisenberg, S Merims, S Frankenburg, A Pato, E Yefenof, R Engelstein, T Peretz, A Machlenkin, M Lotem
PloS one 2015
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
M Freeman-Keller, Y Kim, H Cronin, A Richards, G Gibney, JS Weber
Clinical cancer research 2015
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
J Liu, SJ Blake, MJ Smyth, MW Teng
IBMS BoneKEy 2014
Global Inhibition of DC Priming Capacity in the Spleen of Self-Antigen Vaccinated Mice Requires IL-10
DM Marvel, OJ Finn
Frontiers in immunology 2014
Autoimmune Vitiligo Does Not Require the Ongoing Priming of Naive CD8 T Cells for Disease Progression or Associated Protection against Melanoma
KT Byrne, P Zhang, SM Steinberg, MJ Turk
Journal of immunology (Baltimore, Md. : 1950) 2014
Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells
A Pommier, A Audemard, A Durand, R Lengagne, A Delpoux, B Martin, L Douguet, AL Campion, M Kato, MF Avril, C Auffray, B Lucas, A Prévost-Blondel
Proceedings of the National Academy of Sciences 2013
The delicate balance of melanoma immunotherapy
DE Gyorki, M Callahan, JD Wolchok, CE Ariyan
IBMS BoneKEy 2013
Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity
B Kwong, SA Gai, J Elkhader, KD Wittrup, DJ Irvine
Cancer research 2013
Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer
DC Binder, B Engels, A Arina, P Yu, JM Slauch, YX Fu, T Karrison, B Burnette, C Idel, M Zhao, RM Hoffman, DH Munn, DA Rowley, H Schreiber
Cancer immunology research 2013
A central role for inducible heat-shock protein 70 in autoimmune vitiligo
JA Mosenson, JM Eby, C Hernandez, IC le Poole
Experimental Dermatology 2013
Absence of CD4 T-cell help provides a robust CD8 T-cell response while inducing effective memory in a preclinical model of melanoma
M Muccioli, C Longstaff, F Benencia
Immunotherapy 2012
Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge
JR Baird, KT Byrne, PH Lizotte, S Toraya-Brown, UK Scarlett, MP Alexander, MR Sheen, BA Fox, DJ Bzik, M Bosenberg, DW Mullins, MJ Turk, S Fiering
Journal of immunology (Baltimore, Md. : 1950) 2012
Protective CD8 Memory T Cell Responses to Mouse Melanoma Are Generated in the Absence of CD4 T Cell Help
AL Côté, KT Byrne, SM Steinberg, P Zhang, MJ Turk
PloS one 2011
New perspectives on the role of vitiligo in immune responses to melanoma.
Byrne KT, Turk MJ
Oncotarget 2011
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts